ImmunityBio, Inc.
IBRXNASDAQHealthcare● Active
$7.17
+$0.25(+3.61%)
Market Cap$7.5B
P/E Ratio—
52W High$12.43
52W Low$1.95
ImmunityBio, Inc. (IBRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IBRX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.09
Est. -$0.08 · -12.5%
Revenue
$0.04B
Est. $0.04B · +2.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
IBRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.09 | — | — | — | $0.05B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.08 | -$0.09 | -12.5% | $0.04B | $0.04B | +2.6% |
| ▲ Q1 FY2026 | Feb 23, 2026 | -$0.08 | -$0.06 | +25.0% | $0.04B | $0.04B | -0.2% |
| ▲ Q4 FY2025 | Nov 4, 2025 | -$0.10 | -$0.07 | +30.0% | $0.03B | $0.04B | -15.1% |
| — Q3 FY2025 | Aug 5, 2025 | -$0.10 | -$0.10 | +0.0% | $0.03B | $0.03B | -17.1% |
| ▼ Q2 FY2025 | May 12, 2025 | -$0.12 | -$0.15 | -25.0% | $0.02B | $0.02B | -0.5% |
| ▲ Q1 FY2025 | Mar 3, 2025 | -$0.26 | -$0.15 | +42.3% | $0.01B | $0.01B | -21.5% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.18 | -$0.14 | +22.2% | $0.01B | $0.01B | -32.7% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.09
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.09
EPS Est.
-$0.08
EPS Surpr.
-12.5%
Revenue
$0.04B
Q1 FY2026
Feb 23, 2026Beat
EPS Actual
-$0.06
EPS Est.
-$0.08
EPS Surpr.
+25.0%
Revenue
$0.04B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
-$0.07
EPS Est.
-$0.10
EPS Surpr.
+30.0%
Revenue
$0.03B
Q3 FY2025
Aug 5, 2025
EPS Actual
-$0.10
EPS Est.
-$0.10
EPS Surpr.
+0.0%
Revenue
$0.03B
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$0.15
EPS Est.
-$0.12
EPS Surpr.
-25.0%
Revenue
$0.02B
Q1 FY2025
Mar 3, 2025Beat
EPS Actual
-$0.15
EPS Est.
-$0.26
EPS Surpr.
+42.3%
Revenue
$0.01B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.14
EPS Est.
-$0.18
EPS Surpr.
+22.2%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.12 | $0.13 | $0.15 | 1 |
| Q3 FY2028 | $0.11 | $0.13 | $0.15 | 1 |
| Q2 FY2028 | $0.12 | $0.14 | $0.16 | 1 |
| Q1 FY2028 | $0.10 | $0.11 | $0.13 | 1 |
| Q4 FY2027 | $-0.09 | $-0.08 | $-0.07 | 1 |
| Q3 FY2027 | $-0.09 | $-0.08 | $-0.07 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.3B | $0.4B | $0.4B | 1 |
| Q3 FY2028 | $0.3B | $0.3B | $0.4B | 1 |
| Q2 FY2028 | $0.3B | $0.3B | $0.4B | 1 |
| Q1 FY2028 | $0.3B | $0.3B | $0.4B | 1 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -12.5% | $8.38 | $7.76 | -7.40% |
| ▲ Q1 FY2026 | Feb 23, 2026 | +25.0% | $8.70 | $9.83 | +12.99% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +30.0% | $2.26 | $2.08 | -7.96% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +0.0% | $2.41 | $2.41 | +0.00% |
| ▼ Q2 FY2025 | May 12, 2025 | -25.0% | $2.07 | $2.36 | +14.01% |
| ▲ Q1 FY2025 | Mar 3, 2025 | +42.3% | $3.29 | $2.85 | -13.37% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +22.2% | $5.45 | $4.95 | -9.17% |
| ▼ Q3 FY2024 | Aug 12, 2024 | -17.6% | $4.54 | $4.42 | -2.64% |
Q2 FY2026-7.40%
Report Date
May 7, 2026
EPS Beat/Miss
-12.5%
Price Before
$8.38
Price After
$7.76
Q1 FY2026+12.99%
Report Date
Feb 23, 2026
EPS Beat/Miss
+25.0%
Price Before
$8.70
Price After
$9.83
Q4 FY2025-7.96%
Report Date
Nov 4, 2025
EPS Beat/Miss
+30.0%
Price Before
$2.26
Price After
$2.08
Q3 FY2025+0.00%
Report Date
Aug 5, 2025
EPS Beat/Miss
+0.0%
Price Before
$2.41
Price After
$2.41
Q2 FY2025+14.01%
Report Date
May 12, 2025
EPS Beat/Miss
-25.0%
Price Before
$2.07
Price After
$2.36
Q1 FY2025-13.37%
Report Date
Mar 3, 2025
EPS Beat/Miss
+42.3%
Price Before
$3.29
Price After
$2.85
Q4 FY2024-9.17%
Report Date
Nov 12, 2024
EPS Beat/Miss
+22.2%
Price Before
$5.45
Price After
$4.95
Q3 FY2024-2.64%
Report Date
Aug 12, 2024
EPS Beat/Miss
-17.6%
Price Before
$4.54
Price After
$4.42
Avg Beat Reaction-3.50%
Avg Miss Reaction+1.32%
Beat Rate5 / 8 quarters
Largest Move+14.01% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IBRX ends December
ImmunityBio, Inc. (IBRX) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.09 — missing the analyst consensus of $-0.08 by -12.5%. The next IBRX earnings date is expected around September 1, 2026.
Each quarter, investors track IBRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IBRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IBRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IBRX earnings · 5 questionsImmunityBio, Inc.'s next earnings report is expected around September 1, 2026. IBRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IBRX historically reports after market close (AMC).
IBRX earnings datewhen is IBRX earningsIBRX next earnings datewhen does IBRX report earningsIBRX earnings calendar
▸ Source: FMP · ImmunityBio, Inc. SEC filings · US GAAP · ImmunityBio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026